Which has stronger valuation and earnings, RYTM or NBTX?

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rhythm Pharmaceuticals $189.76M 35.84 -$196.54M -$3.13 N/A Nanobiotix $29.64M 65.54 -$27.11M N/A N/A

Does the media refer more to RYTM or NBTX?

In the previous week, Rhythm Pharmaceuticals had 14 more articles in the media than Nanobiotix. MarketBeat recorded 16 mentions for Rhythm Pharmaceuticals and 2 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat Nanobiotix's score of 0.67 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, MIRM or NBTX?

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mirum Pharmaceuticals $569.61M 11.34 -$23.36M -$13.61 N/A Nanobiotix $29.64M 65.54 -$27.11M N/A N/A

Does the media refer more to MIRM or NBTX?

In the previous week, Mirum Pharmaceuticals had 9 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 2 mentions for Nanobiotix. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Nanobiotix's score of 0.67 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NBTX or LNTH?

Lantheus has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $29.64M 65.54 -$27.11M N/A N/A Lantheus $1.54B 4.21 $233.56M $4.15 24.01

Is NBTX or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity. Company Net Margins Return on Equity Return on Assets Nanobiotix N/A N/A N/A Lantheus 18.05% 29.32% 15.00%

Does the media refer more to NBTX or LNTH?

In the previous week, Lantheus had 12 more articles in the media than Nanobiotix. MarketBeat recorded 14 mentions for Lantheus and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.67 beat Lantheus' score of 0.33 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, COGT or NBTX?

Nanobiotix has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Nanobiotix $29.64M 65.54 -$27.11M N/A N/A

Is COGT or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Nanobiotix N/A N/A N/A

Does the media refer more to COGT or NBTX?

In the previous week, Cogent Biosciences had 9 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Cogent Biosciences and 2 mentions for Nanobiotix. Cogent Biosciences' average media sentiment score of 1.53 beat Nanobiotix's score of 0.67 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NBTX or PTCT?

PTC Therapeutics has higher revenue and earnings than Nanobiotix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nanobiotix $29.64M 65.54 -$27.11M N/A N/A PTC Therapeutics $1.73B 3.26 $682.64M -$0.58 N/A

Does the media prefer NBTX or PTCT?

In the previous week, PTC Therapeutics had 20 more articles in the media than Nanobiotix. MarketBeat recorded 22 mentions for PTC Therapeutics and 2 mentions for Nanobiotix. PTC Therapeutics' average media sentiment score of 0.93 beat Nanobiotix's score of 0.67 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Nanobiotix (NBTX) Competitors

$38.38 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$38.48 +0.10 (+0.25%)

As of 07/31/2026 07:59 PM Eastern

Compare

NBTX vs. RYTM, MIRM, LNTH, COGT, and PTCT

Should you buy Nanobiotix stock or one of its competitors? MarketBeat compares Nanobiotix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nanobiotix include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Cogent Biosciences (COGT), and PTC Therapeutics (PTCT).

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	35.84	-$196.54M	-$3.13	N/A
Nanobiotix	$29.64M	65.54	-$27.11M	N/A	N/A

Rhythm Pharmaceuticals currently has a consensus price target of $138.73, indicating a potential upside of 39.78%. Nanobiotix has a consensus price target of $37.33, indicating a potential downside of 2.73%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Rhythm Pharmaceuticals had 14 more articles in the media than Nanobiotix. MarketBeat recorded 16 mentions for Rhythm Pharmaceuticals and 2 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 1.18 beat Nanobiotix's score of 0.67 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market.

Nanobiotix has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Nanobiotix's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Nanobiotix	N/A	N/A	N/A

38.8% of Nanobiotix shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Rhythm Pharmaceuticals beats Nanobiotix on 8 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Mirum Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Nanobiotix has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Nanobiotix's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Nanobiotix	N/A	N/A	N/A

Mirum Pharmaceuticals presently has a consensus target price of $143.40, indicating a potential upside of 35.35%. Nanobiotix has a consensus target price of $37.33, indicating a potential downside of 2.73%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	11.34	-$23.36M	-$13.61	N/A
Nanobiotix	$29.64M	65.54	-$27.11M	N/A	N/A

38.8% of Nanobiotix shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mirum Pharmaceuticals had 9 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 2 mentions for Nanobiotix. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Nanobiotix's score of 0.67 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Nanobiotix on 9 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Lantheus?

Nanobiotix (NASDAQ:NBTX) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Lantheus had 12 more articles in the media than Nanobiotix. MarketBeat recorded 14 mentions for Lantheus and 2 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.67 beat Lantheus' score of 0.33 indicating that Nanobiotix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64M	65.54	-$27.11M	N/A	N/A
Lantheus	$1.54B	4.21	$233.56M	$4.15	24.01

Nanobiotix has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Nanobiotix's net margin of 0.00%. Lantheus' return on equity of 29.32% beat Nanobiotix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
Lantheus	18.05%	29.32%	15.00%

Nanobiotix presently has a consensus target price of $37.33, suggesting a potential downside of 2.73%. Lantheus has a consensus target price of $109.71, suggesting a potential upside of 10.11%. Given Lantheus' stronger consensus rating and higher probable upside, analysts clearly believe Lantheus is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lantheus	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Lantheus beats Nanobiotix on 10 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Cogent Biosciences presently has a consensus target price of $45.90, suggesting a potential upside of 17.90%. Nanobiotix has a consensus target price of $37.33, suggesting a potential downside of 2.73%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cogent Biosciences is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Nanobiotix	$29.64M	65.54	-$27.11M	N/A	N/A

38.8% of Nanobiotix shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Nanobiotix	N/A	N/A	N/A

Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Cogent Biosciences had 9 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Cogent Biosciences and 2 mentions for Nanobiotix. Cogent Biosciences' average media sentiment score of 1.53 beat Nanobiotix's score of 0.67 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cogent Biosciences beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to PTC Therapeutics?

Nanobiotix (NASDAQ:NBTX) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

38.8% of Nanobiotix shares are held by institutional investors. 3.5% of Nanobiotix shares are held by company insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nanobiotix has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nanobiotix	$29.64M	65.54	-$27.11M	N/A	N/A
PTC Therapeutics	$1.73B	3.26	$682.64M	-$0.58	N/A

Nanobiotix has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Nanobiotix's return on equity of 0.00% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nanobiotix	N/A	N/A	N/A
PTC Therapeutics	-3.80%	-362.45%	-1.32%

In the previous week, PTC Therapeutics had 20 more articles in the media than Nanobiotix. MarketBeat recorded 22 mentions for PTC Therapeutics and 2 mentions for Nanobiotix. PTC Therapeutics' average media sentiment score of 0.93 beat Nanobiotix's score of 0.67 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nanobiotix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	14 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Nanobiotix currently has a consensus target price of $37.33, suggesting a potential downside of 2.73%. PTC Therapeutics has a consensus target price of $95.75, suggesting a potential upside of 40.79%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe PTC Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

PTC Therapeutics beats Nanobiotix on 9 of the 15 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.94B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	N/A	7.38	282.30	24.66
Price / Sales	65.54	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	-19.48	16.96	10.98	6.07
Net Income	-$27.11M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-4.48%	-1.76%	-0.60%	-0.44%
1 Month Performance	-0.05%	-8.38%	-5.20%	-4.81%
1 Year Performance	469.86%	48.40%	62.01%	18.61%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	1.3 of 5 stars	$38.38 flat	$37.33 -2.7%	+469.9%	$1.94B	$29.64M	N/A	100	Gap Up
RYTM Rhythm Pharmaceuticals	3.4024 of 5 stars	$105.95 +1.3%	$138.29 +30.5%	+12.4%	$7.26B	$189.76M	N/A	140	Positive News Upcoming Earnings
MIRM Mirum Pharmaceuticals	3.3361 of 5 stars	$117.34 +0.6%	$143.40 +22.2%	+103.7%	$7.16B	$521.31M	N/A	140	Positive News Upcoming Earnings
LNTH Lantheus	3.1989 of 5 stars	$106.86 +2.4%	$110.43 +3.3%	+41.2%	$6.95B	$1.55B	25.74	1,193	Upcoming Earnings Analyst Upgrade
COGT Cogent Biosciences	2.1996 of 5 stars	$39.43 +3.0%	$45.90 +16.4%	+241.5%	$6.74B	N/A	N/A	80	Positive News Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Summary

How does Nanobiotix compare to Mirum Pharmaceuticals?

Summary

How does Nanobiotix compare to Lantheus?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Summary

How does Nanobiotix compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. RYTM, MIRM, LNTH, COGT, and PTCT

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Which has stronger valuation and earnings, RYTM or NBTX?

Do analysts prefer RYTM or NBTX?

Does the media refer more to RYTM or NBTX?

Which has more volatility and risk, RYTM or NBTX?

Is RYTM or NBTX more profitable?

Do insiders & institutionals hold more shares of RYTM or NBTX?

Summary

How does Nanobiotix compare to Mirum Pharmaceuticals?

Which has more risk and volatility, MIRM or NBTX?

Is MIRM or NBTX more profitable?

Do analysts recommend MIRM or NBTX?

Which has higher earnings & valuation, MIRM or NBTX?

Do insiders & institutionals have more ownership in MIRM or NBTX?

Does the media refer more to MIRM or NBTX?

Summary

How does Nanobiotix compare to Lantheus?

Does the media refer more to NBTX or LNTH?

Which has stronger valuation and earnings, NBTX or LNTH?

Which has more risk & volatility, NBTX or LNTH?

Do institutionals & insiders believe in NBTX or LNTH?

Is NBTX or LNTH more profitable?

Do analysts recommend NBTX or LNTH?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Do analysts rate COGT or NBTX?

Which has better valuation and earnings, COGT or NBTX?

Do insiders and institutionals believe in COGT or NBTX?

Is COGT or NBTX more profitable?

Which has more volatility & risk, COGT or NBTX?

Does the media refer more to COGT or NBTX?

Summary

How does Nanobiotix compare to PTC Therapeutics?

Do institutionals and insiders believe in NBTX or PTCT?

Which has more risk & volatility, NBTX or PTCT?

Which has stronger valuation & earnings, NBTX or PTCT?

Is NBTX or PTCT more profitable?

Does the media prefer NBTX or PTCT?

Do analysts rate NBTX or PTCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools